AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Ventre Medical Associates Hosts Quarterly Meet and Greets to Offer Tour of its Deep TMS and Depression Clinic

March 28, 2019

OAKLAND PARK, Fla., March 28, 2019 (GLOBE NEWSWIRE) -- Ventre Medical Associates, a full-service psychiatric clinic offering expert consultation, evaluation and treatment of mental health disorders, announced that it will be hosting quarterly meet and greets, in which local clinicians will have the opportunity to tour its Deep TMS and depression clinic. The open house events will feature the advanced treatment of BrainsWay ’s Deep Transcranial Magnetic Stimulation (Deep TMS), a non-invasive, non-medication treatment that is FDA-cleared for the treatment of depression.

Eric Tirado, Ventre Medical patient, said, “I have battled with depression for over 20 years, having undergone various hardships, including discovering that I was HIV positive, had a serious medical condition that required surgery, and losing my partner of almost two decades to a massive heart attack. I’ve been treated with psychotherapy and many medications, and while I found some relief here and there, I didn’t have lasting remission. But the most significant improvement that I have seen in treating my depression was with Deep TMS. I am so thankful for Ventre Medical’s constant care over the years and for introducing me to Deep TMS.”

With 15 million Americans suffering from depression, up to two-thirds of which do not respond to or tolerate medication, patients are seeking new treatments with greater efficacy. Deep TMS is a treatment in which magnetic fields are non-invasively sent to deep structures of the brain through a cushioned helmet. The patients remain awake for the 20 to 30 minute treatment sessions, do not require anesthesia and can immediately return to daily activities. The treatment has been used on tens of thousands of patients in leading hospitals and psychiatry practices across the country and has demonstrated very positive remission and response rates.

“Our mission has always been to ensure the highest quality of therapy and maximize success for our patients struggling with depression, and with Deep TMS, we are able to offer our patients the best treatments,” said Dr. Peter Ventre, founder and CEO of Ventre Medical Associates. “We are really looking forward to greeting local clinicians so that they can gain firsthand experience of our proven and effective methodology and approach.”

The quarterly meet and greets will take place on the following dates: April 4, June 7 and August 5. These events are geared towards clinical therapists, medical providers, agencies and hospitals and are by invitation only. If you are interested in attending, please email: Maite@ventremedical.com or call 954-773-5698 for more information.

About Ventre Medical AssociatesVentre Medical Associates is a full-service psychiatric clinic offering expert consultation, evaluation, and treatment of mental health disorders. We provide additional outpatient psychiatric services at detox, PHP and IOP locations throughout the Broward and Palm Beach Counties. Many of our psychiatrists serve on staff at some of the area’s leading hospitals and are experts at treating patients in acute care settings. Our team utilizes the most up-to-date psychiatric techniques and specializes in a variety of treatments for every stage of life: children and adolescents, adult and the elderly, substance abuse patients and addiction recovery.

About BrainsWay BrainsWay Ltd./ BrainsWay USA (TASE: BRIN) is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders. The medical system developed and manufactured by the company is based on a unique breakthrough technology called Deep TMS, which can reach significant depth and breadth of the brain and produce broad stimulation and functional modulation of targeted brain areas. In the U.S., the Company’s device has been FDA cleared for the treatment of major depressive disorder (MDD) since 2013 and is now FDA cleared (De-Novo) for the treatment of Obsessive-Compulsive Disorder (OCD). The Company’s systems have also received CE clearance and are sold worldwide for the treatment of various brain disorders.

Media Contact:Sharon Golubchik Brainsway@antennagroup.com 609-418-0058